Aplidin (plitidepsin) to be re-evaluated by the EMA for Multiple Myeloma

  • The European Commission (EC) has acknowledged that an expert from the Scientific Advisory Group, who was developing a rival product was allowed to participate in the Marketing Authorization procedure for Aplidin (plitidepsin).
  • The EC requests the European Medicines Agency, EMA, to re-evaluate the application for Aplidin in Multiple Myeloma.
  • This exceptional decision supports what PharmaMar has always maintained, namely that there was a conflict of interest among the EMA experts who evaluated the therapy.
  • The Company will demand the reassessment process to be conducted with absolute impartiality, equality and transparency by the EMA.

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib